åè¨ç®çãéæããããã«ãæ¬çºæã¯ãåè¨çªå·ï¼«ï¼£ï¼£ï¼­ï¼ï¼ï¼ï¼ï¼ï¼°ã§å¯è¨ãããã¹ãã³ã´ã¢ãã¹å±ãã¯ããªã¢ãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨çªå·ï¼«ï¼£ï¼£ï¼­ï¼ï¼ï¼ï¼ï¼ï¼°ã§å¯è¨ãããã¢ã¹ãã«ã®ã«ã¹å±ã«ããæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨ã¹ãã³ã´ã¢ãã¹å±ãã¯ããªã¢ãæ¶²ä½å¹é¤ããå¹é¤æ¶²ã«å¥ã«æ¶²ä½å¹é¤ããåè¨ã®ã¢ã¹ãã«ã®ã«ã¹å±ã«ãèæ ªã¾ãã¯èæ ªãå«ãã å¹é¤æ¶²ãå ãã¦å¹é¤ããå·¥ç¨ãå«ãèè¤åä½ã®æ··åå¹é¤æ¹æ³ãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨æ··åå¹é¤æ¹æ³ã§å¹é¤ãããèè¤åä½ã®å¹é¤æ¶²ãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨æ··åå¹é¤æ¹æ³ã§å¹é¤ãããèè¤åä½ã®å¹é¤æ¶²ããåé¢ãããä¸è¨åå­¦å¼ï¼ã¾ãã¯åå­¦å¼ï¼ã§è¡¨ããããååç©ãæä¾ããã In order to achieve the above object, the present invention provides a Spingomonas bacterium, deposited under the deposit number KCCM10888P.

The present invention also provides Aspergillus fungi deposited under the deposit number KCCM10889P.

The present invention also provides a mixed culture method of a fungal complex comprising a step of adding and culturing the above-mentioned Aspergillus fungus strain or a culture solution containing the strain separately in a culture solution obtained by liquid culture of the Spingomonas bacterium. provide.

The present invention also provides a culture solution of the fungal complex cultured by the mixed culture method.

Moreover, this invention provides the compound represented by following Chemical formula 1 or Chemical formula 2 isolate | separated from the culture solution of the fungal complex cultured by the said mixed culture method.

ï½ã¯ãã¤ãªã¦ã®åæ°ã§ããï¼ãï¼ã§ï¼åã³ n is the number of sulfur and is 1 to 4; and

ï¼¸ã¯ãæ°´ç´ ã¾ãã¯ã¢ã«ã­ã«åºã§ãããäºãã«åããã¾ãã¯ç°ãªãããã¹ã¦ã®éå¯¾ç§°ç­ç´ ã§ã®ç°æ§ä½ãå«ãã

ã¾ããæ¬çºæã¯ãåè¨æ··åå¹é¤æ¹æ³ã§å¹é¤ãããèè¤åä½ã®å¹é¤æ¶²ã¾ãã¯åè¨ååç©ãå«ãæçå¤ãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨æ··åå¹é¤æ¹æ³ã§å¹é¤ãããèè¤åä½ã®å¹é¤æ¶²ã¾ãã¯åè¨ååç©ãå«ãæèå¤ãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨å¹é¤æ¶²åã³ããããæ½åºããååç©ã®æçå¤ã®è£½é ã«ãããä½¿ç¨ãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨å¹é¤æ¶²åã³ããããæ½åºããååç©ã®æèå¤ã®è£½é ã«ãããä½¿ç¨ãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨å¹é¤æ¶²åã³ããããæ½åºããååç©ãå«ãçäºé²ç¨åã³å¥åº·æ¹åç¨ã®å¥åº·é£åãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨å¹é¤æ¶²åã³ããããæ½åºããååç©ãå«ãèææäºé²ç¨åã³å¥åº·æ¹åç¨ã®å¥åº·é£åãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨å¹é¤æ¶²åã³ããããæ½åºããååç©ã®æ²»ççæå¹éãåä½ã«æä¸ããå·¥ç¨ãå«ãçæ²»çæ¹æ³ãæä¾ããã

åæã«ãæ¬çºæã¯ãåè¨å¹é¤æ¶²åã³ããããæ½åºããååç©ã®æ²»ççæå¹éãåä½ã«æä¸ããå·¥ç¨ãå«ãèæææ²»çæ¹æ³ãæä¾ããã

ä»¥ä¸ãæ¬çºæãè©³ããèª¬æããã

æ¬çºæã¯ãåè¨çªå·ï¼«ï¼£ï¼£ï¼­ï¼ï¼ï¼ï¼ï¼ï¼°ã§å¯è¨ãããã¹ãã³ã´ã¢ãã¹å±ãã¯ããªã¢èæ ªï¼«ï¼­ï¼«âï¼ï¼ï¼ãæä¾ããã

æ¬çºæè ç­ã¯ãã¤ã³ã³ã¯é±å±±å é¨ã§é ¸æ§åº¦ï¼ï½ï¼¨ï¼ï¼ï¼ï¼ã®æ°´ãæ¡åå¾ãé å¿åé¢ãã¦æ²æ®¿ç©ãå¾ããåè¨æ²æ®¿ç©ãççé£å¡©æ°´ã«æ¸æ¿ãã¦å¸éããå¾ãå¹å°ã«æ¥ç¨®å¾ãå¹é¤ããªããåä¸èæ ªãåé¢åã³é¸å¥ãã¦æ¶²ä½å¹å°ã«æ¥ç¨®ããå¾ãåã³å¹é¤ãããç¢ºä¿ãããèæ ªç¨®ã®åæã¯ãæè²ä½ï¼¤ï¼®ï¼¡ãåé¢ãã¦ä¸è¨ã®ãããªï¼ï¼ï¼³ ï½ï¼¤ï¼®ï¼¡å¡©åºé åãåæãã¦æ±ºå®ãããã®çµæãèæ ªï¼«ï¼­ï¼«âï¼ï¼ï¼ã¯ãã¹ãã³ã´ã¢ãã¹å±ï¼ï¼³ï½ï½ï½ï½ï½ï½ï½ï½ï½ï½ï½ ï½ï½ï¼ï¼¡ï¼ï¼¸ï¼¸ï½ï½ï¼âï¼ï¼ã¨ï¼ï¼ï¼ï¼ï¼ ã®ç¸åæ§ãç¤ºããã¨ãç¢ºèªãã¦ãåè¨ï¼«ï¼­ï¼«âï¼ï¼ï¼ãã¹ãã³ã´ã¢ãã¹å±ã«å±ããæ°è¦ç¨®ã§ãããã¨ãåãã£ããï¼«ï¼­ï¼«âï¼ï¼ï¼ã¯ããã¡ããã¯ããã¯ã¹å¹å°ã§é»è²ç²æ¶²æ§ã³ã­ãã¼ãå½¢æãã¦ãçé·ã®ããã«ç¡é ¸å¡©ã¨ç¡«é ¸å¡©ãå¿ é çã«è¦æ±ãããã¨ãç¢ºèªãã¦ãã°ã©ã é°æ§ã«ã³èã§ãããã¨ãåãã£ãï¼å³ï¼åã³å³ï¼åç §ï¼ãåè¨èæ ªï¼«ï¼­ï¼«âï¼ï¼ï¼ã¯ãéå½å¾®çç©ä¿å­ã»ã³ã¿ã¼ã«ï¼ï¼ï¼ï¼å¹´ï¼ï¼æï¼æ¥ä»ãã§å¯è¨ããï¼åè¨çªå·ï¼ï¼«ï¼£ï¼£ï¼­ï¼ï¼ï¼ï¼ï¼ï¼°ï¼ã

æ¬çºæã®æ°è¦ãªèæ ªï¼«ï¼­ï¼«âï¼ï¼ï¼ã®ï¼ï¼ï¼³ ï½ï¼¤ï¼®ï¼¡å¡©åºé åãä¸è¨ã«ç¤ºãï¼

AGAGTTTGAT CCTGGCTCAG AACGAACGCT GGCGGCATGC CTAATACATG CAAGTCGAAC GATCACTTCG GTGGTAGTGG CGCACGGGTG CGTAACGCGT GGGAATCTGC CCTTGGGTTC GGAATAACAG TTGGAAACGA CTGCTAATAC CGGATGATGA CGTAAGTCCA AAGATTTATC GCCCAAGGAT GAGCCCGCGT AGGATTAGCT AGTTGGTGAG GTAAAGGCTC ACCAAGGCAA CGATCCTTAG CTGGTCTGAG AGGATGATCA GCCACACTGG GACTGAGACA CGGCCCAGAC TCCTACGGGA GGCAGCAGTA GGGAATATTG GACAATGGGG GCAACCCTGA TCCAGCAATG CCGCGTGAGT GATGAAGGCC TTAGGGTTGT AAAGCTCTTT TACCCGAGAT GATAATGACA GTATCGGGAG AATAAGCTCC GGCTAACTCC GTGCCAGCAG CCGCGGTAAT ACGGAGGGAG CTAGCGTTGT TCGGAATTAC TGGGCGTAAA GCGCACGTAG GCGGCGATTT AAGTCAGAGG TGAAAGCCCG GGGCTCAACC CCGGAACTGC CTTTGAGACT GGATTGCTAG AATCTTGGAG AGGCGGGTGG AATTCCGAGT GTAGAGGTGA AATTCGTAGA TATTCGGAAG AACACCAGTG GCGAAGGCGG CCCGCTGGAC AAGTATTGAC GCTGAGGTGC GAAAGCGTGG GGAGCAAACA GGATTAGATA CCCTGGTAGT CCACGCCGTA AACGATGATA ACTAGCTGCC GGGGCACATG GTGTTTCGGT AGCGCAGCTA ACGCATTAAG TTATCCGCCT GGGGAGTACG GTCGCAAGAT TAAAACTCAA AGGAATTGAC GGGGGCCTGC ACAAGCGGTG GAGCATGTGG TTTAATTCGA AGCAACGCGC AGAACCTTAC CAACGTTTGA CATCCCTATC GCGGATCGTG GAGACACTTT CCTTCAGTTC GGCTGGATAG GTGACAGGTG CTGCATGGCT GTCGTCAGCT CGTGTCGTGA GATGTTGGGT TAAGTCCCGC AACGAGCGCA ACCCTCGCCT TTAGTTGCCA GCATTTAGTT GGGTACTCTA AAGGAACCGC CGGTGATAAG CCGGAGGAAG GTGGGGATGA CGTCAAGTCC TCATGGCCCT TACGCGTTGG GCTACACACG TGCTACAATG GCGACTACAG TGGGCAGCCA CTCCGCGAGG AGGAGCTAAT CTCCAAAAGT CGTCTCAGTT CGGATTGTTC TCTGCAACTC AAGAGCATGA AGGCGGAATC GCTAGTAATC GCGGATCAGC ATGCCGCGGT GAATACGTTC CCAGGCCTTG TACACACCGC CCGTCACACC ATGGGAGTTG GATTCACCTG AAGGCGCTGC GCTAACTCGC AAGAGAGGCA GGCGACCACG GTGGGTTTAG CGACTGGGGT GAAGTCGTAA CAAGGTAGCC GTAGGGGAAC CTGCGGCTGG ATCACCTCCT Tï¼é åçªå·ï¼ï¼

ã¾ããæ¬çºæã¯ãåè¨çªå·ï¼«ï¼£ï¼£ï¼­ï¼ï¼ï¼ï¼ï¼ï¼°ã§å¯è¨ãããã¢ã¹ãã«ã®ã«ã¹å±ï¼ï¼¡ï½ï½ï½ ï½ï½ï½ï½ï½ï½ï½ï¼ã«ãèæ ªï¼«ï¼­ï¼£âï¼ï¼ï¼ãæä¾ãããåè¨èæ ªï¼«ï¼­ï¼£âï¼ï¼ï¼ã¯ãéå½å¾®çç©ä¿å­ã»ã³ã¿ã¼ã«ï¼ï¼ï¼ï¼å¹´ï¼ï¼æï¼æ¥ä»ãã§å¯è¨ããï¼åè¨çªå·ï¼ï¼«ï¼£ï¼£ï¼­ï¼ï¼ï¼ï¼ï¼ï¼°ï¼ã

åè¨èæ ªï¼«ï¼­ï¼£âï¼ï¼ï¼ã®èéè½ã¯ãåæã«ã¯ç½è²ã®ç¾æ¯æ¨¡æ§ãå¸¯ã³ãªããæéãçµã¤ã«ã¤ãã¦ä¸­å¤®é¨åã®éç·é åãæ¿ããªããªããåºããªããåã³ç°è²ã®ä¸­å¤®é¨åãå½¢æããã¦ãã¢ã¹ãã«ã®ã«ã¹âããã¬ã¼ããï¼ï¼¡ï½ï½ï½ ï½ï½ï½ï½ï½ï½ï½ ï½ï½ï½ï½ï½ï½ï½ï½ï½ï¼ã«ãã®èéè½ã¨åä¸ãªå½¢æ ãå¸¯ã³ã¦ããï¼å³ï¼åç §ï¼ï¼ãã§ã³ã»ã¬ã¸ã³ãå¾®çç©å³éãç¬¬ï¼å·»ï¼ï½ï¼ï¼ï¼ï¼âï¼ï¼ï¼ãï¼ï¼ï¼ï¼å¹´ï¼ãï¼«ï¼­ï¼£âï¼ï¼ï¼ã®èç³¸ä½ã¯éå£ãæãã¦ãã¦ãã¢ã¹ãã«ã®ã«ã¹ï¼ï¼¡ï½ï½ï½ ï½ï½ï½ï½ï½ï½ï½ï¼å±ã«ãã®ç¹å¾´çãªåçå­é ­ãç¤ºããï¼å³ï¼åç §ï¼ï¼ãã§ã³ã»ã¬ã¸ã³ãå¾®çç©å³éãï¼ï¼ï¼ï¼å¹´ï¼ç¬¬ï¼å·»ï¼ï½ï¼ï¼ï¼ï¼âï¼ï¼ï¼ï¼ãã¾ããï¼«ï¼­ï¼£âï¼ï¼ï¼ããã¡ããã¯ããã¯ã¹å¹å°ã§æ¶²ä½å¹é¤ãã¦ç£çãããäºæ¬¡ä»£è¬ç£ç©ãé«éæ¶²ä½ã¯ã­ããã°ã©ãã£ã¼è³ªéåææ©ï¼ï¼¨ï¼°ï¼¬ï¼£âï¼­ï¼³ï¼åã³æ ¸ç£æ°å ±é³´åå å¨ï¼ï¼®ï¼­ï¼²ï¼ãç¨ãã¦åæããçµæãã¢ã¹ãã«ã®ã«ã¹âããã¬ã¼ããã®ç¹å¾´çãªæåã§ããã°ãªãªãã­ã·ã³ï¼¡ï¼ï¼§ï½ï½ï½ï½ï½ï½ï½ï½ï¼åã³ã·ã¥ã¼ã­ãã³ï¼¡ï¼ï¼°ï½ï½ ï½ï½ï½ï½ï½ï½ ï¼¡ï¼ã®å­å¨ãç¢ºèªãããï¼ï¼©ï½ï½ï½ï½ï½ï½ï¼ï¼¹ï¼ç­ï¼ï¼ªï½ï½ï½ï½ï½ï½ ï½ï½ ï¼¡ï½ï½ï½ï½ï½ï½ï½ï½ï½ï¼ï¼ï¼ï¼ï¼å¹´ï¼ç¬¬ï¼ï¼å·»ï¼ï½ï¼ï¼ï¼ï¼âï¼ï¼ï¼ï¼ãåè¨å½¢æ å­¦çåã³åå­¦çç¹å¾´ãéãã¦èæ ªï¼«ï¼­ï¼£âï¼ï¼ï¼ã¯ãã¢ã¹ãã«ã®ã«ã¹âããã¬ã¼ããã«å±ããã«ãã§ããã¨æ±ºå®ããã¢ã¹ãã«ã®ã«ã¹âããã¬ã¼ããï¼«ï¼­ï¼£âï¼ï¼ï¼ã¨åä»ããã

ã¾ããæ¬çºæã¯ãåè¨ã¹ãã³ã´ã¢ãã¹å±æ°è¦ãã¯ããªã¢èæ ªãæ¶²ä½å¹é¤ããå¹é¤æ¶²ã«å¥ã«æ¶²ä½å¹é¤ãããã¢ã¹ãã«ã®ã«ã¹å±ã«ãèæ ªã¾ãã¯èæ ªãå«ãã å¹é¤æ¶²ãå ãã¦å¹é¤ããå·¥ç¨ãå«ãèè¤åä½ã®æ··åå¹é¤æ¹æ³ãæä¾ããã

åè¨æ··åå¹é¤æ¹æ³ã¯ãã¹ãã³ã´ã¢ãã¹å±æ°è¦ãªãã¯ããªã¢èæ ªåã³ã¢ã¹ãã«ã®ã«ã¹å±ã«ãèæ ªãï¼ï¼ï¼ï¼ï¼ï¼ï¼ï¼ãï¼ï¼ï¼ï¼ï¼ï¼ï¼ï¼ã®å²åã§æ··åãããã¨ãå¥½ã¾ãããï¼ï¼ ï¼ï¼ï¼ï¼ï¼ï¼ã®å²åã§æ··åãããã¨ãããã«å¥½ã¾ããããããã«éå®ãããªãã

æ¬çºæè ç­ã¯ãæ°è¦ãã¯ããªã¢èæ ªï¼«ï¼­ï¼«âï¼ï¼ï¼ã¨ã«ãèæ ªï¼«ï¼­ï¼£âï¼ï¼ï¼ã¯ãããããæ¶²ä½å¹å°ã«æ¥ç¨®ããå¾ãå¹é¤ãããã¹ãã³ã´ã¢ãã¹å±èæ ªï¼«ï¼­ï¼«âï¼ï¼ï¼ã®å¹é¤æ¶²ï¼ãªããã«ã«ã«ãèæ ªï¼«ï¼­ï¼£âï¼ï¼ï¼ãå«ãã å¹é¤æ¶²ï¼ï¼ï¼ãã¤ã¯ã­ãªããã«ãå ãã¦æ··åå¹é¤ããé«éæ¶²ä½ã¯ã­ããã°ã©ãã£ã¼ãç¨ãã¦æ··åå¹é¤æ¶²ãåæãã¦æ°ããååç©ã®ç£çæç¡ãç¢ºèªããããã¯ããªã¢èæ ªï¼«ï¼­ï¼«âï¼ï¼ï¼åã³ã«ãèæ ªï¼«ï¼­ï¼£âï¼ï¼ï¼ãããããï¼ï¼æ¥éåä¸å¹é¤ããå¹é¤æ¶²ã®åæã®çµæãã°ãªãªãããªã³ç­ã¯å ¨ãå­å¨ããªãã£ãããï¼«ï¼­ï¼«âï¼ï¼ï¼ã¨ï¼«ï¼­ï¼£âï¼ï¼ï¼ãï¼ï¼æ¥éæ··åå¹é¤ããå¹é¤æ¶²ã¯ãä¿ææéï¼ï¼ï¼ï¼ï¼ï¼åã®ãã¼ã¯ã§ã°ãªãªãããªã³ï¼¡ããï¼ï¼ï¼ï¼ï¼ï¼åã®ãã¼ã¯ã§ã°ãªãªãããªã³ï¼¢ãç¤ºãããï¼«ï¼­ï¼«âï¼ï¼ï¼ã¨ï¼«ï¼­ï¼£âï¼ï¼ï¼ã®æ··åå¹é¤ï¼æ¥ç®ããéæ¥ã§æ··åå¹é¤æ¶²ãåæããçµæãã°ãªãªãããªã³ç­ã¯æ··åå¹é¤ï¼æ¥ç®ããç£çããå§ããã

ã¾ããæ¬çºæã¯ãåè¨æ··åå¹é¤æ¹æ³ã§å¹é¤ãããèè¤åä½ã®å¹é¤æ¶²ãæä¾ããã

ã¾ããæ¬çºæã¯ãåè¨æ··åå¹é¤æ¹æ³ã§å¹é¤ãããèè¤åä½ã®å¹é¤æ¶²ããåé¢ãããä¸è¨ã®åå­¦å¼ï¼ã¾ãã¯åå­¦å¼ï¼ã§è¡¨ããããååç©ãæä¾ããã

åè¨ååç©ã¯ãæ°è¦ãªååç©ã¨ãã¦æ¬çºæè ã«ãã£ã¦ã°ãªãªãããªã³ï¼ï¼§ï½ï½ï½ï½ï½ï½ï½ï½ï½ï½ï¼ã¨å½åãããã X is hydrogen or an alkyl group, the same or different from each other, including isomers at all asymmetric carbons.

The present invention also provides a culture solution of the fungal complex cultured by the mixed culture method or an anticancer agent comprising the compound.

Moreover, this invention provides the antimicrobial agent containing the culture solution of the fungal complex cultured by the said mixed culture method, or the said compound.

The present invention also provides use of the culture solution and a compound extracted therefrom in the production of an anticancer agent.

The present invention also provides use of the culture solution and a compound extracted therefrom in the production of an antibacterial agent.

The present invention also provides a health food for cancer prevention and health improvement comprising the culture solution and a compound extracted therefrom.

The present invention also provides a health food for preventing bacterial infection and improving health, comprising the culture solution and a compound extracted therefrom.

The present invention also provides a method for treating cancer comprising the step of administering to the individual a therapeutically effective amount of the culture solution and a compound extracted therefrom.

At the same time, the present invention provides a method for treating bacterial infection comprising the step of administering to the individual a therapeutically effective amount of the culture solution and a compound extracted therefrom.

The present invention will be described in detail below.

The present invention provides Spingomonas bacterium strain KMK-001 deposited under accession number KCCM10888P.

The present inventors collected water having an acidity (pH) of 3.0 inside the Inkoku mine, and then centrifuged to obtain a precipitate. The precipitate was suspended and diluted in physiological saline, inoculated into a medium, a single strain was isolated and selected while culturing, inoculated into a liquid medium, and then cultured again. The analysis of the secured strain species was determined by separating the chromosomal DNA and analyzing the 16S rDNA base sequence as described below, and as a result, the strain KMK-001 was identified as the genus Spingomonas (Sphingomonas sp. A1XXyl1-5). It was confirmed that the homology was 98.0%, and it was found that the KMK-001 was a new species belonging to the genus Spingomonas. KMK-001 was found to be a Gram-negative gonococcus by confirming that it formed a yellow mucous colony in the Czabek Docs medium and required nitrates and sulfates for growth. 1 and 2). The strain KMK-001 was deposited with the Korean Preservation Center on November 7, 2007 (Accession Number: KCCM10888P).

The 16S rDNA base sequence of the novel strain KMK-001 of the present invention is shown below:

AGAGTTTGAT CCTGGCTCAG AACGAACGCT GGCGGCATGC CTAATACATG CAAGTCGAAC GATCACTTCG GTGGTAGTGG CGCACGGGTG CGTAACGCGT GGGAATCTGC CCTTGGGTTC GGAATAACAG TTGGAAACGA CTGCTAATAC CGGATGATGA CGTAAGTCCA AAGATTTATC GCCCAAGGAT GAGCCCGCGT AGGATTAGCT AGTTGGTGAG GTAAAGGCTC ACCAAGGCAA CGATCCTTAG CTGGTCTGAG AGGATGATCA GCCACACTGG GACTGAGACA CGGCCCAGAC TCCTACGGGA GGCAGCAGTA GGGAATATTG GACAATGGGG GCAACCCTGA TCCAGCAATG CCGCGTGAGT GATGAAGGCC TTAGGGTTGT AAAGCTCTTT TACCCGAGAT GATAATGACA GTATCGGGAG AATAAGCTCC GGCTAACTCC GTGCCAGCAG CCGCGGTAAT ACGGAGGGAG CTAGCGTTGT TCGGAATTAC TGGGCGTAAA GCGCACGTAG GCGGCGATTT AAGTCAGAGG TGAAAGCCCG GGGCTCAACC CCGGAACTGC CTTTGAGACT GGATTGCTAG AATCTTGGAG AGGCGGGTGG AATTCCGAGT GTAGAGGTGA AATTCGTAGA TATTCGGAAG AACACCAGTG GCGAAGGCGG CCCGCTGGAC AAGTATTGAC GCTGAGGTGC GAAAGCGTGG GGAGCAAACA GGATTAGATA CCCTGGTAGT CCACGCCGTA AACGATGATA ACTAGCTGCC GGGGCACATG GTGTTTCGGT AGCGCAGCTA ACGCATTAAG TTATCCGCCT GGGGAGTACG GTCGCAAGAT TAAAACTCAA AGGAATTGAC GGGGGCCTGC ACAAGCGGTG GAGCATGTGG TTTAATTCGA AGCAACGCGC AGAACCTTAC CAACGTTTGA CATCCCTATC GCGGATCGTG GAGACACTTT CCTTCAGTTC GGCTGGATAG GTGACAGGTG CTGCATGGCT GTCGTCAGCT CGTGTCGTGA GATGTTGGGT TAAGTCCCGC AACGAGCGCA ACCCTCGCCT TTAGTTGCCA GCATTTAGTT GGGTACTCTA AAGGAACCGC CGGTGATAAG CCGGAGGAAG GTGGGGATGA CGTCAAGTCC TCATGGCCCT TACGCGTTGG GCTACACACG TGCTACAATG GCGACTACAG TGGGCAGCCA CTCCGCGAGG AGGAGCTAAT CTCCAAAAGT CGTCTCAGTT CGGATTGTTC TCTGCAACTC AAGAGCATGA AGGCGGAATC GCTAGTAATC GCGGATCAGC ATGCCGCGGT GAATACGTTC CCAGGCCTTG TACACACCGC CCGTCACACC ATGGGAGTTG GATTCACCTG AAGGCGCTGC GCTAACTCGC AAGAGAGGCA GGCGACCACG GTGGGTTTAG CGACTGGGGT GAAGTCGTAA CAAGGTAGCC GTAGGGGAAC CTGCGGCTGG ATCACCTCCT T (SEQ ID NO: 1)

The present invention also provides Aspergillus fungal strain KMC-901 deposited under accession number KCCM10889P. The strain KMC-901 was deposited at the Korean Preservation Center on November 7, 2007 (Accession Number: KCCM10889P).

The bacterial colonies of the strain KMC-901 initially have a white wool pattern, and as time passes, the blue-green region of the central part becomes darker and wider, and a gray central part is formed again. Aspergillus-Fumigertsov (Aspergillus fumigatus) has the same form as fungal colonies (see FIG. 3) (Chun Gajin, Microbial Encyclopedia, Volume 3: p.192-194, 2007). The mycelium of KMC-901 had a septum and showed characteristic conidial heads of Aspergillus fungi (see FIG. 4) (Chong Gajin, Microbiology Encyclopedia, 2007, Vol. 3, p.192-194). Moreover, the result of having analyzed the secondary metabolite produced by liquid culture of KMC-901 in the zabek dox medium using the high performance liquid chromatography mass spectrometer (HPLC-MS) and the nuclear magnetic resonance spectrometer (NMR). In addition, the existence of gliotoxin A and Pseurotin A, which are characteristic components of Aspergillus-Fumigatuft, has been confirmed (Igarash, Y. et al. Journal of Antibiotic, 2004, Vol. 57, p. 50). 748-754). Through the morphological and chemical characteristics, the strain KMC-901 was determined to be a mold belonging to Aspergillus-Fumigatsuv and named Aspergillus-Fumigatsuf KMC-901.

The present invention also relates to a mixed culture method of a fungal complex comprising a step of culturing by adding a culture solution containing an Aspergillus fungus strain or a strain separately cultured in a culture solution obtained by liquid culture of the novel spingomonas bacterium strain. I will provide a.

In the mixed culture method, a novel bacterial strain of the genus Spingomonas and a fungal strain of Aspergillus are preferably mixed at a ratio of 1000: 1.0 to 1000: 0.1, and mixed at a ratio of 100: 0.5. Is more preferable, but not limited thereto.

The present inventors cultured the novel bacterial strain KMK-001 and the mold strain KMC-901 after inoculating them in a liquid medium. Production of new compounds by adding 500 microliters of culture solution containing mold strain KMC-901 to 1 liter of culture solution of Spingomonas sp. Strain KMK-001 and analyzing the mixed culture solution using high performance liquid chromatography The presence or absence was confirmed. As a result of analysis of the culture solution obtained by culturing the bacterial strain KMK-001 and the mold strain KMC-901 for 15 days each, no glionitrin was present, but KMK-001 and KMC-901 were mixed and cultured for 15 days. The solution showed glionithrin A with a peak at a retention time of 18.072 minutes and glionithrin B with a peak at 18.767 minutes. As a result of analyzing the mixed culture solution every other day from the 2nd day of the mixed culture of KMK-001 and KMC-901, glionitrin and the like began to be produced from the 8th day of the mixed culture.

The present invention also provides a culture solution of the fungal complex cultured by the mixed culture method.

Moreover, this invention provides the compound represented by following Chemical formula 1 or Chemical formula 2 isolate | separated from the culture solution of the fungal complex cultured by the said mixed culture method.

The compound has been named by the inventor as a new compound, Glionitrins.

ï½ã¯ãã¤ãªã¦ã®åæ°ãç¤ºããï¼ãï¼ã§ããã n shows the number of sulfur and is 1-4.

ï¼¸ã¯ãæ°´ç´ ãã¾ãã¯ï¼£ï¼ãï¼£ï¼ã¢ã«ã­ã«åºã§ãããäºãã«åããã¾ãã¯ç°ãªãããã¹ã¦ã®éå¯¾ç§°ç­ç´ ã§ã®ç°æ§ä½ãå«ãã

æ¬çºæã®åè¨ã°ãªãªãããªã³ååç©ã¯ãä¸è¨ã®å·¥ç¨ãå«ãæ¹æ³ã«ãã£ã¦è£½é ãããã

ï¼ï¼ã¹ãã³ã´ã¢ãã¹å±èæ ªï¼«ï¼­ï¼«âï¼ï¼ï¼ã®å¹é¤æ¶²ï¼ãªããã«ã«ï¼ï¼ï¼ãã¤ã¯ã­ãªããã«ã®ã«ãèæ ªï¼«ï¼­ï¼£âï¼ï¼ï¼ãå«ãã å¹é¤æ¶²ãå ãã¦æ··åå¹é¤ããå¾ãå¹é¤æ¶²ã«ææ©æº¶åªã¾ãã¯å¸çæ¨¹èãå ãã¦æ½åºããå·¥ç¨ï¼

ï¼ï¼å·¥ç¨ï¼ï¼ã®æ½åºç©ãæ¸å§ä¹¾ç¥ããå¾ãã«ã©ã ã¯ã­ããã°ã©ãã£ã¼ãç¨ãã¦åç»ç©ãå¾ãå·¥ç¨ï¼åã³

ï¼ï¼å·¥ç¨ï¼ï¼ã®åç»ç©ããããã«ã«ã©ã ã¯ã­ããã°ã©ãã£ã¼ãç¨ãã¦ååç©ãåé¢ç²¾è£½ããå·¥ç¨ã

åè¨è£½é æ¹æ³ã«ããã¦ãå·¥ç¨ï¼ï¼ã®æ··åå¹é¤ã¯ãï¼ï¼æ¥ãï¼ï¼æ¥éå¹é¤ãããã¨ãå¥½ã¾ãããï¼ï¼æ¥ãï¼ï¼æ¥éå¹é¤ãããã¨ãããã«å¥½ã¾ããããããã«éå®ãããªããåè¨ææ©æº¶åªã¯ãé ¢é ¸ã¨ãã«ããã¿ãã¼ã«ãå¡©åã¡ãã¬ã³ã¾ãã¯ã¯ã­ã­ãã«ã ãä½¿ç¨ãããã¨ãå¥½ã¾ããããããã«éå®ãããªããåè¨æ½åºã¯ãè¶ è¨çæ½åºãé«å§æ½åºã¾ãã¯è¶ é³æ³¢æ½åºæ³ãªã©ã®æ½åºè£ ç½®ãç¨ããæ¹æ³ãã¾ãã¯ãï¼¸ï¼¡ï¼¤åã³ï¼¨ï¼°âï¼ï¼ãå«ãã å¸çæ¨¹èãç¨ããæ¹æ³ã«ä»£æ¿å¯è½ã§ããããããã«éå®ãããªããæ½åºæãæº¶åªãæ··åå¹é¤æ¶²åéã®ï¼ãªããï¼åæ·»å ãã¦æ½åºãããã¨ãå¥½ã¾ãããï¼åæ·»å ãã¦æ½åºãããã¨ãããã«å¥½ã¾ãããå¸¸æ¸©ã§æ½åºãããã¨ãå¥½ã¾ããããããã«éå®ãããã®ã§ã¯ãªããä½µãã¦ãæ½åºåæ°ã¯ãï¼ãï¼åãå¥½ã¾ãããï¼ååè¦æ½åºãããã¨ãããã«å¥½ã¾ããããããã«éå®ããããã®ã§ã¯ãªãã

åè¨è£½é æ¹æ³ã«ããã¦ãå·¥ç¨ï¼ï¼ã®æ¸å§ä¹¾ç¥ã¯ãåè»¢çç©ºæ¿ç¸®æ©ï¼ï¼²ï½ï½ï½ï½ï½ ï¼¶ï½ï½ï½ï½ï½ ï¼¥ï½ï½ï½ï½ï½ï½ï½ï½ï½ï¼ãä½¿ç¨ãããã¨ãå¥½ã¾ããããããã«éå®ãããªããåè¨æ¸å§ä¹¾ç¥æã®æ¸©åº¦ã¯ãï¼ï¼ãï¼ï¼âãå¥½ã¾ãããï¼ï¼âãããã«å¥½ã¾ãããããã«éå®ãããªãã

åè¨è£½é æ¹æ³ã«ããã¦ãå·¥ç¨ï¼ï¼ã¾ãã¯å·¥ç¨ï¼ï¼ã®ã«ã©ã ã¯ã­ããã°ã©ãã£ã¼ã¯ãã·ãªã«ã²ã«ãã»ãããã¯ã¹ãï¼²ï¼°âï¼ï¼ãããªã¢ããããã¨ãã¼ã«ï¼ï¼´ï½ï½ï½ï½ï½ ï½ï½ï½ï¼åã³ï¼¸ï¼¡ï¼¤æ¨¹èãããªãç¾¤ããé¸æãããå å¡«å¤ãç¨ããã«ã©ã ãç¨ããã«ã©ã ã¯ã­ããã°ã©ãã£ã¼ãéè¡ãã¦æ´»æ§ååç©ãåé¢åã³ç²¾è£½ãããã¨ãã§ãããã«ã©ã ã¯ã­ããã°ã©ãã£ã¼ã¯ãå¿ è¦ã«å¿ãã¦é©åãªå å¡«å¤ãé¸æãã¦æ°åå®æ½ãããã¨ãã§ããæº¶åªã«ã¯ã­ã­ãã«ã ï¼ï¼£ï¼¨ï¼£ï½ï¼ï¼âã¡ã¿ãã¼ã«ãã¨ãã«ã¢ã»ãã¼ãâã¡ã¿ãã¼ã«ãã¸ã¯ã­ã­ã¡ã¿ã³âã¡ã¿ãã¼ã«ãã¡ã¿ãã¼ã«âæ°´ã¾ãã¯ã¢ã»ããããªã«âæ°´ãç¨ãããã¨ãã§ããããããã«éå®ãããªãã

æ¬çºæè ç­ã¯ãåè¨é ¢é ¸ã¨ãã«æ½åºæ¶²ãæ¸å§ä¹¾ç¥ãã¦å¾ãæ½åºç©ãéç¸ã«ã©ã ã¯ã­ããã°ã©ãã£ã¼ãç¨ãã¦å ­åã®åç»ã«åãããæº¶é¢æ¡ä»¶ã¯ãæ°´ã¨ã¢ã»ããããªã«ãä½¿ç¨ããï¼ï¼ï¼ ã¢ã»ããããªã«ï¼æ°´ã§å§ãã¦ãï¼ï¼ï¼ ãã¤ã¢ã»ããããªã«ã®å«éãå¢å ãããï¼ï¼ï¼ï¼ ã¡ã¿ãã¼ã«ãæçµæµåºæº¶åªã«ä½¿ç¨ãããããããå¾ãããåç»ç©ãé«éæ¶²ä½ã¯ã­ããã°ã©ãã£ã¼æ³ãç¨ãã¦ä¸»æåãåæããçµæãï¼ï¼ï¼ ã¢ã»ããããªã«ï¼æ°´åç»ç©ããæ°è¦ãªã°ãªãªãããªã³ãç¢ºèªãããåè¨åç»ç©ã«ããã«é ¢é ¸ã¨ãã«åã³å¡©åã¡ãã¬ã³ãæº¶åªã«ä½¿ç¨ãã¦ï¼ï¼ï¼ å¡©åã¡ãã¬ã³ï¼é ¢é ¸ã¨ãã«åã³ï¼ï¼ï¼ å¡©åã¡ãã¬ã³ï¼é ¢é ¸ã¨ãã«ã®ã¢ã¤ã½ã¯ã©ãã£ãã¯æº¶åªæº¶é¢æ¡ä»¶ã§é ç¸æ¶²ä½ã¯ã­ããã°ã©ãã£ã¼æ³ãéãã¦ç²¾è£½ãããä¿ææéï¼ï¼åã«ä¸è¨åå­¦å¼ï¼ã§è¡¨ããããã°ãªãªãããªã³ï¼¡ã¨ä¿ææéï¼ï¼åã«åå­¦å¼ï¼ã§è¡¨ããããã°ãªãªãããªã³ï¼¢ãããããå¾ãã X is hydrogen or a C 1 -C 5 alkyl group, the same or different from each other, including isomers in all asymmetric carbon.

The said glionithrin compound of this invention is manufactured by the method including the following process.

1) A step of adding a culture solution containing 500 microliters of the fungal strain KMC-901 to 1 liter of the culture solution of Spingomonas sp. KMK-001, mixing and culturing, and then adding an organic solvent or an adsorption resin to the culture solution for extraction ;

2) After drying the extract of step 1) under reduced pressure, a step of obtaining a fraction using column chromatography; and 3) further separating and purifying the compound from the fraction of step 2) using column chromatography. Process.

In the production method, the mixed culture in step 1) is preferably performed for 10 to 20 days, more preferably 12 to 18 days, but is not limited thereto. The organic solvent is preferably ethyl acetate, butanol, methylene chloride or chloroform, but is not limited thereto. The extraction can be replaced with a method using an extraction apparatus such as supercritical extraction, high pressure extraction or ultrasonic extraction method, or a method using an adsorption resin containing XAD and HP-20, but is not limited thereto. . At the time of extraction, it is preferable to add 1 to 3 times as much solvent as the mixed culture solution, and it is more preferable to add 2 times and extract. Although it is preferable to extract at normal temperature, it is not limited to this. In addition, the number of extractions is preferably 1 to 5 times, and more preferably 3 times repetitive extraction, but is not limited thereto.

In the production method, the drying under reduced pressure in step 2) is preferably performed using a rotary vacuum evaporator, but is not limited thereto. The temperature during the drying under reduced pressure is preferably 20 to 40 Â° C, more preferably 30 Â° C, but is not limited thereto.

In the production method, the column chromatography of step 2) or step 3) uses a column using a packing material selected from the group consisting of silica gel, Sepadex, RP-18, polyamide, Toyopearl, and XAD resin. Column chromatography can be performed to separate and purify the active compound. The column chromatography can be carried out several times by selecting an appropriate packing as required, and the solvent is chloroform (CHCl 3 ) -methanol, ethyl acetate-methanol, dichloromethane-methanol, methanol-water or acetonitrile- Water can be used, but is not limited thereto.

The inventors of the present invention separated the extract obtained by drying the ethyl acetate extract under reduced pressure into six fractions using reverse phase column chromatography. Elution conditions used water and acetonitrile, starting with 20% acetonitrile / water, increasing the acetonitrile content by 20%, and using 100% methanol as the final effluent solvent. As a result of analyzing the main component of the fraction obtained from this using a high performance liquid chromatography method, a novel glionitrin was confirmed from the 60% acetonitrile / water fraction. The fraction was further purified through normal phase liquid chromatography using isocratic solvent elution conditions of 90% methylene chloride / ethyl acetate and 60% methylene chloride / ethyl acetate using ethyl acetate and methylene chloride as solvents. Glynitrin A represented by the following chemical formula 3 was obtained at a retention time of 10 minutes, and glinitrin B represented by the chemical formula 4 was obtained at a retention time of 15 minutes.